Heron Therapeutics, Inc. (HRTX)
Largest Insider Buys in Sector
HRTX Stock Price History Chart
HRTX Stock Performance
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or …
Insider Activity of Heron Therapeutics, Inc.
Over the last 12 months, insiders at Heron Therapeutics, Inc. have bought $0 and sold $0 worth of Heron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Heron Therapeutics, Inc. have bought $3.69M and sold $395,403 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $27,250 was made by Forbes William P (EVP, Chief Development Officer) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Heron Therapeutics, Inc.
| 2023-11-17 | EVP, Chief Development Officer | 25,000 0.0179% | $1.09 | $27,250 | +123.15% | |||
| 2023-11-16 | Chief Executive Officer | 150,000 0.1065% | $0.92 | $137,970 | +158.32% | |||
| 2023-11-16 | EVP, Chief Financial Officer | 85,000 0.0584% | $0.89 | $75,599 | +158.32% | |||
| 2023-11-16 | EVP, Chief Development Officer | 50,000 0.0363% | $0.94 | $46,995 | +158.32% | |||
| 2023-07-21 | director | 2.49M 2.0703% | $1.37 | $3.41M | +55.80% | |||
| 2022-05-03 | Sale | EVP, Drug Development | 1,504 0.0015% | $4.76 | $7,154 | -38.95% | ||
| 2021-12-21 | Sale | director | 300 0.0003% | $9.73 | $2,920 | -56.73% | ||
| 2021-12-21 | Sale | director | 250 0.0002% | $9.73 | $2,432 | -56.73% | ||
| 2021-09-21 | Sale | director | 600 0.0006% | $12.31 | $7,384 | -54.08% | ||
| 2021-09-21 | Sale | director | 500 0.0005% | $12.30 | $6,148 | -54.08% | ||
| 2021-06-21 | Sale | director | 600 0.0006% | $15.20 | $9,118 | -40.10% | ||
| 2021-06-21 | Sale | director | 500 0.0005% | $15.20 | $7,601 | -40.10% | ||
| 2021-05-03 | Sale | EVP, Drug Development | 3,058 0.0032% | $17.66 | $54,017 | -39.34% | ||
| 2021-04-15 | Sale | director | 600 0.0006% | $17.51 | $10,508 | -38.97% | ||
| 2021-04-06 | Sale | director | 500 0.0005% | $17.22 | $8,610 | -33.90% | ||
| 2021-01-14 | Sale | EVP, Chief Operating Officer | 1,654 0.0018% | $18.09 | $29,920 | -29.12% | ||
| 2021-01-08 | Sale | EVP, Chief Operating Officer | 7,142 0.0039% | $9.83 | $70,219 | -32.19% | ||
| 2020-12-22 | Sale | EVP, Drug Development | 20,000 0.0176% | $16.50 | $330,000 | -32.95% | ||
| 2020-05-01 | Sale | Executive VP, Drug Development | 2,316 0.0013% | $6.98 | $16,176 | +25.16% | ||
| 2019-11-29 | Sale | Executive VP, Drug Development | 48,000 0.0274% | $13.00 | $624,000 | -35.68% |
Insider Historical Profitability
| Morgan Adam | director | 6986744 4.5937% | $1.07 | 1 | 0 | |
| TANG KEVIN C | director | 5799810 3.8133% | $1.07 | 19 | 1 | +4.62% |
| Collard Craig A | Chief Executive Officer | 186496 0.1226% | $1.07 | 1 | 0 | |
| RIEPENHAUSEN PETER | director | 179332 0.1179% | $1.07 | 2 | 0 | |
| Quart Barry D | Chief Executive Officer | 94652 0.0622% | $1.07 | 3 | 4 | <0.0001% |
Institutional Investor Ownership
| Helm Capital Management LLC | $74M | 17.73 | 26.71M | 0% | +$0 | 2.19 | |
| OrbiMed | $28.01M | 6.71 | 10.11M | +70.56% | +$11.59M | 0.22 | |
| The Vanguard Group | $22.48M | 5.39 | 8.11M | -2.69% | -$621,022.91 | <0.0001 | |
| BlackRock | $20.18M | 4.84 | 7.29M | +1.73% | +$342,582.51 | <0.0001 | |
| Velan Capital | $19.35M | 4.64 | 6.99M | 0% | +$0 | 10.53 |